Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Executive Summary
Wyeth will invest $60 mil. in Effexor manufacturing capacity expansion in 2003, CFO Kenneth Martin told the Credit Suisse First Boston investor conference Nov. 14 in Phoenix
You may also be interested in...
Merck Sees Chance To “Repatriate” Cash To U.S.; GSK Wants To Ship Out
Merck sees an opportunity to bring back cash to the U.S. should a tax change allowing companies to "repatriate" holdings at foreign subsidiaries be enacted by Congress this year
Merck Sees Chance To “Repatriate” Cash To U.S.; GSK Wants To Ship Out
Merck sees an opportunity to bring back cash to the U.S. should a tax change allowing companies to "repatriate" holdings at foreign subsidiaries be enacted by Congress this year
Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason
Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product